Communiqués Silence Therapeutics plc

Actions

SLN

US82686Q1013

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 18:39:11 10/08/2026			Varia. 5j.	Varia. 1 janv.
14,78 ^USD	+23,72%		+49,63%	+162,83%

17:27	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent légèrement lors de la séance de lundi	MT
14:50	Silence Therapeutics plc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

13:31	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile	BU
13:16	Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results	BU
09/08	Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera	BU
11/06	Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera	BU
27/05	Silence Therapeutics to Participate in Jefferies Global Healthcare Conference	BU
12/05	Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference	BU
07/05	Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results	BU
05/03	Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results	BU
15/12	Silence Therapeutics Announces Leadership Changes	BU
12/11	Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference	BU
06/11	Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights	BU
24/10/25	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera	AQ
23/10/25	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)	BU
02/09/25	Silence Therapeutics to Participate in September Investor Conferences	BU
07/08/25	Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights	BU
12/06/25	Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera	BU
08/05/25	Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights	BU
06/05/25	Silence Therapeutics Welcomes Tim McInerney to Board of Directors	BU
05/03/25	Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference	BU
27/02/25	Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update	BU
13/02/25	Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025	BU
02/01/25	Silence Therapeutics : Regulation FD Disclosure Form 8 K	PU
09/12/24	Silence Therapeutics : also announces first subject dosed in Phase 2 study of divesiran in PV patients Company reinforces commitment to prioritize divesiran development as the first in class siRNA in PV Form 6 K	PU
09/12/24	Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting	BU
26/11/24	Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference	BU